The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Secondary Hyperparathyroidism
For patient iPTH level > 400 pg/mL: 10 mcg orally or 4 mcg intravenously following dialysis three times a week.
For patient iPTH level reduced < 50% and above 300 pg/mL:
Increase maintenance dose by 2.5 mcg orally or 1 to 2 mcg intravenously at 8 week intervals as necessary to bring iPTH level below 300 pg/mL.
For patient iPTH level 150 to 300 pg/mL: maintain current oral or intravenous dose.
For patient iPTH level < 100 pg/mL: suspend oral or intravenous dose dosage for 1 week, then resume oral dosage at least 2.5 mcg lower or intravenous dosage at least 1 mcg lower than the last administered dose.
The maximum recommended oral dosage is 20 mcg three times a week (60 mcg total weekly dose). Intravenous dosages higher than 18 mcg a week (total weekly dose) have not been studied.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Current dosage recommendations for doxercalciferol in patients undergoing peritoneal dialysis are the same as those for hemodialysis patients, according to the manufacturer.
Weekly monitoring of serum calcium, phosphorus, and iPTH levels is recommended during doxercalciferol titration. In the event of hypercalcemia or hyperphosphatemia or should the product of serum calcium and phosphorus concentrations exceed 70, doxercalciferol should be withheld. Following an appropriate calcium and/or phosphate reduction, therapy should be continued at an oral dosage at least 2.5 mcg or intravenous dosage at least 1 mcg less than the last administered dose.
More about doxercalciferol
- Other brands: Hectorol